205 related articles for article (PubMed ID: 18586929)
1. 18F-Fluorodeoxyglucose positron emission tomography for monitoring response to sorafenib treatment in patients with hepatocellular carcinoma.
Siemerink EJ; Mulder NH; Brouwers AH; Hospers GA
Oncologist; 2008 Jun; 13(6):734-5; author reply 736-7. PubMed ID: 18586929
[No Abstract] [Full Text] [Related]
2. Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib.
Lee JH; Park JY; Kim DY; Ahn SH; Han KH; Seo HJ; Lee JD; Choi HJ
Liver Int; 2011 Sep; 31(8):1144-9. PubMed ID: 21745288
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib in hepatocellular carcinoma.
Josephs DH; Ross PJ
Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
[TBL] [Abstract][Full Text] [Related]
4. [Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma].
Reig M; Matilla A; Bustamante J; Castells L; de La Mata M; Delgado M; Moreno JM; Forner A; Varela M
Gastroenterol Hepatol; 2010 Dec; 33(10):741-52. PubMed ID: 20851505
[No Abstract] [Full Text] [Related]
5. Sorafenib in advanced hepatocellular carcinoma.
Palmer DH
N Engl J Med; 2008 Dec; 359(23):2498; author reply 2498-9. PubMed ID: 19065750
[No Abstract] [Full Text] [Related]
6. Sorafenib in advanced hepatocellular carcinoma.
Copur MS
N Engl J Med; 2008 Dec; 359(23):2498; author reply 2498-9. PubMed ID: 19065701
[No Abstract] [Full Text] [Related]
7. Sorafenib in liver cancer--just the beginning.
Roberts LR
N Engl J Med; 2008 Jul; 359(4):420-2. PubMed ID: 18650519
[No Abstract] [Full Text] [Related]
8. Sorafenib in advanced hepatocellular carcinoma.
Spinzi G; Paggi S
N Engl J Med; 2008 Dec; 359(23):2497-8; author reply 2498-9. PubMed ID: 19052134
[No Abstract] [Full Text] [Related]
9. [Hepatocellular carcinoma - long-term treatable disease].
Fínek J
Klin Onkol; 2012; 25(4):287-9. PubMed ID: 22920170
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib: where do we go from here?
Siegel AB; Olsen SK; Magun A; Brown RS
Hepatology; 2010 Jul; 52(1):360-9. PubMed ID: 20578152
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib for liver cancer: the horizon broadens.
Johnson P; Billingham L
Lancet Oncol; 2009 Jan; 10(1):4-5. PubMed ID: 19111238
[No Abstract] [Full Text] [Related]
12. Sorafenib.
Hasskarl J
Recent Results Cancer Res; 2010; 184():61-70. PubMed ID: 20072831
[TBL] [Abstract][Full Text] [Related]
13. Major achievements in hepatocellular carcinoma.
Bruix J; Llovet JM
Lancet; 2009 Feb; 373(9664):614-6. PubMed ID: 19231618
[No Abstract] [Full Text] [Related]
14. Target therapy for hepatocellular carcinoma: is sorafenib for everybody?
Daniele B; Di Maio M
J Clin Gastroenterol; 2009; 43(5):389-90. PubMed ID: 19564813
[No Abstract] [Full Text] [Related]
15. Computed tomography findings of sorafenib-treated hepatic tumors in patients with advanced hepatocellular carcinoma.
Kim MJ; Choi JI; Lee JS; Park JW
J Gastroenterol Hepatol; 2011 Jul; 26(7):1201-6. PubMed ID: 21371120
[TBL] [Abstract][Full Text] [Related]
16. [Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations].
Boige V; Barbare JC; Rosmorduc O;
Gastroenterol Clin Biol; 2008 Jan; 32(1 Pt. 1):3-7. PubMed ID: 18341970
[No Abstract] [Full Text] [Related]
17. Molecular therapy for the treatment of hepatocellular carcinoma.
Greten TF; Korangy F; Manns MP; Malek NP
Br J Cancer; 2009 Jan; 100(1):19-23. PubMed ID: 19018262
[TBL] [Abstract][Full Text] [Related]
18. [Hepatocellular carcinoma].
Yamashita T; Arai K; Kaneko S
Nihon Rinsho; 2010 Oct; 68(10):1861-5. PubMed ID: 20954330
[TBL] [Abstract][Full Text] [Related]
19. Speeding up cancer-drug development.
Burton A
Lancet Oncol; 2006 Oct; 7(10):798. PubMed ID: 17039633
[No Abstract] [Full Text] [Related]
20. Contrast-enhanced ultrasonography for evaluating antiangiogenic treatment in hepatocellular carcinoma. A long way from research to clinical practice.
Spârchez Z
Med Ultrason; 2012 Jun; 14(2):85-6. PubMed ID: 22675706
[No Abstract] [Full Text] [Related]
[Next] [New Search]